Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talabostat - BioXcel Therapeutics

Next Previous
X
Search
Drug Profile

Talabostat - BioXcel Therapeutics

Alternative Names: BXCL 701; PT-100; Talabostat mesilate; Talabostat mesylate; Val-boro-Pro

Latest Information Update: 11 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tufts University School of Medicine
  • Developer BioXcel Therapeutics; Georgetown University; M. D. Anderson Cancer Center; Midatech Pharma US; National Cancer Institute (USA); OnkosXcel Therapeutics
  • Class Antineoplastics; Boronic acids; Dipeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Pancreatic cancer; Malignant melanoma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Prostate cancer
  • Phase I/II Pancreatic cancer
  • Phase I Acute myeloid leukaemia
  • Preclinical Small cell lung cancer
  • Suspended Myelodysplastic syndromes; Soft tissue sarcoma; Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Malignant melanoma; Neutropenia; Non-small cell lung cancer

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase II trial in Adenocarcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 18 Apr 2024 BioXcel Therapeutics anticipates a meeting with FDA regarding development of talabostat in Prostate cancer (small cell neuroendocrine prostate cancer) in 2024
  • 18 Apr 2024 BioXcel Therapeutics plans a phase Ib/II trial for Small cell lung cancer in 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top